[HTML][HTML] In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a …
E Kolokotroni, D Dionysiou, C Veith… - PLoS Computational …, 2016 - journals.plos.org
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
[HTML][HTML] The INTEGRATE project: delivering solutions for efficient multi-centric clinical research and trials
H Kondylakis, B Claerhout, M Keyur, L Koumakis… - Journal of biomedical …, 2016 - Elsevier
The objective of the INTEGRATE project (http://www. fp7-integrate. eu/) that has recently
concluded successfully was the development of innovative biomedical applications focused …
concluded successfully was the development of innovative biomedical applications focused …
[HTML][HTML] Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S …
Background As in many cancer types, the G1/S restriction point (RP) is deregulated in Acute
Lymphoblastic Leukemia (ALL). Hyper-phosphorylated retinoblastoma protein (hyper-pRb) …
Lymphoblastic Leukemia (ALL). Hyper-phosphorylated retinoblastoma protein (hyper-pRb) …